Clinical Trials · NCT00221299
Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- University of California, Davis
- Enrollment
- 60
- Start date
- Sep 2005
- Locations
- 1 site, United States
- Primary endpoint
- Bone Mineral Density (BMD): Examine the Pattern and Effect of BMD Changes at Hip and Spine Measured by DXA Every 6 Months.